Pharmaceutical turnaround story trading at $0.615 vs $0.94 fair value. 54% upside potential with 31% European growth and operational recovery to 8.1% EBITDA margins.
View noteAVOID rating with fair value $4.20 vs current $14.82. Strong 19% revenue growth and 95% recurring revenue model undermined by extreme 253% overvaluation and cloud disintermediation risk.
View noteMLG trades at 68% discount to peers despite operational recovery. Fair value $1.00 vs current $0.80 with 25% upside potential.
View noteDeep value opportunity at $0.41 vs $2.49 fair value. EBITDA margins recovering from 13.1% trough. Canadian operations prove model works with 4.4% SSS growth.
View noteTrading at $0.395 vs $0.54 fair value. Binary transformation from depleting iron ore to gold development. Strong balance sheet with execution risk.
View noteHOLD rating with $3.34 fair value vs $4.24 current price. Strong infrastructure exposure offset by integration risks and overvaluation.
View noteHOLD rating with $13.07 fair value vs $10.94 current price. Partnership income surged 202% to 38% of profit. 6.7% dividend yield with transformation execution risk.
View noteHOLD rating with $0.40 fair value vs $0.37 current price. Strong 20.5% ROIC and underground expansion offset by peak cycle positioning and execution risks.
View noteHOLD rating with $0.35 fair value vs $0.32 current price. SaaS transformation progressing with 75% recurring revenue, 95%+ retention, but execution risks during leadership transition.
View noteLycopodium trades at $12.00 vs fair value $16.62, offering 38.5% upside through technical differentiation, SAXUM integration, and critical minerals recovery with 32.8% ROIC.
View noteHOLD rating with A$14.73 fair value vs A$14.61 current price. Strategic HRE monopoly outside China driving 32% EBITDA margins by FY27, though Malaysian regulatory renewal March 2026 creates binary risk.
View notePremium Tasmanian whisky producer trading at $0.76 vs $0.54 fair value. Business quality 3.98/10, EBITDA margins -20%, requiring $18-45m funding. International expansion critical but execution risks high.
View note